Trial Profile

An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of Nous-PEV, With Pembrolizumab, in Patients With Unresectable Stage III / IV Cutaneous Melanoma and With Stage IV NSCLC (PDL1≥ 50%)

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 24 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NOUS PEV (Primary) ; Pembrolizumab
Indications Malignant melanoma; Non-small cell lung cancer; Skin cancer; Squamous cell cancer
Focus Adverse reactions; First in man
Sponsors Nouscom

20 Mar 2025 Status changed from active, no longer recruiting to discontinued.
18 Apr 2023 New translational and biomarker data presented in the Nouscom Media Release.
15 Mar 2023 According to a Nouscom media release, data from this study will be presented in a Late-Breaking session at the 2023 American Association for Cancer Research (AACR) Annual Meeting held in in Orlando, FL from 14th to 19th April.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com